Personal Genome Diagnostics Inc Pipeline Insight and Therapeutic Assessment Reviewed in 2017

“Personal Genome Diagnostics” Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories. PGD offers custom solutions such as cancer whole genome analysis, cancer genome germline analysis, cancer bioinformatic analysis and ctDNA analyses, among others. The company caters its products and services to academics, biotechnology and pharmaceutical companies, and contract research organizations. PGD is headquartered in Baltimore, Maryland, the US.

Request For Free Sample - https://www.marketresearchhub.com/enquiry.php?type=S&repid=1386159

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Personal Genome Diagnostics Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Browse Full Report With TOC - https://www.marketresearchhub.com/report/personal-genome-diagnostics-inc-product-pipeline-analysis-2017-update-report.html

Table of Contents
Table of Contents 2
List of Tables 3

List of Figures 3
Personal Genome Diagnostics Inc Company Overview 4
Personal Genome Diagnostics Inc Company Snapshot 4
Personal Genome Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Personal Genome Diagnostics Inc Pipeline Analysis Overview 7
Personal Genome Diagnostics Inc - Key Facts 7
Personal Genome Diagnostics Inc - Major Products and Services 8
Personal Genome Diagnostics Inc Pipeline Products by Development Stage 9
Personal Genome Diagnostics Inc Pipeline Products Overview 11
MutatorDETECT Assay 11
MutatorDETECT Assay Product Overview 11
PGDx Plasma Based Diagnostic Kit 12

PGDx Plasma Based Diagnostic Kit Product Overview 12
PGDx Tissue Based Diagnostic Kit 13
PGDx Tissue Based Diagnostic Kit Product Overview 13
PlasmaSelect-R Liquid Biopsy Test - CLIA 14
PlasmaSelect-R Liquid Biopsy Test - CLIA Product Overview 14
Personal Genome Diagnostics Inc - Key Competitors 15
Personal Genome Diagnostics Inc - Key Employees 16
Personal Genome Diagnostics Inc - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18

Personal Genome Diagnostics Inc, Recent Developments 18
Jun 14, 2017: Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT Liquid Biopsy Cancer Profiling Assay 18
Jun 02, 2017: Personal Genome Diagnostics Highlights its Patent-Pending Microsatellite Instability Testing Technology as FDA Approves Keytruda for MSI Tumors 18
Mar 30, 2017: Personal Genome Diagnostics Announces AACR Annual Meeting 2017 Presentations and Awards 19
Mar 28, 2017: Personal Genome Diagnostics' Expanded PlasmaSELECT 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology 20

Continue…

Enquire About this Report - https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1386159

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : www.marketresearchhub.com/
Read Industry News at - www.industrynewsanalysis.com/

This release was published on openPR.